Is Augmentin (amoxicillin-clavulanate) an effective treatment for a patient with Clostridioides difficile (C. difficile) infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 12, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Augmentin Should NOT Be Used to Treat C. difficile Infection

Augmentin (amoxicillin-clavulanate) is not an effective treatment for C. difficile infection and should never be used for this purpose. In fact, Augmentin is a well-recognized risk factor for causing C. difficile infection and can worsen existing disease 1, 2, 3.

Why Augmentin Fails for CDI

Augmentin lacks activity against C. difficile in the clinical setting. While laboratory studies show that C. difficile isolates may be sensitive to amoxicillin-clavulanate in vitro 4, this does not translate to clinical efficacy for treating CDI 4. The drug is actually classified as a high-risk antibiotic that promotes C. difficile overgrowth and toxin production 2, 3.

The Correct Treatment Approach

For Initial CDI Episodes

Oral vancomycin 125 mg four times daily for 10 days is the first-line treatment for both mild-moderate and severe C. difficile infection 1, 2, 3. This represents a major shift from older guidelines that favored metronidazole, as vancomycin demonstrates superior clinical outcomes with high-quality evidence 1, 2.

  • Fidaxomicin 200 mg twice daily for 10 days is an equally effective alternative, particularly valuable for elderly patients or those with multiple comorbidities who face higher recurrence risk 1, 2, 3.

  • Metronidazole should only be used in resource-limited settings where vancomycin or fidaxomicin are unavailable, and only for nonsevere initial episodes 1. Avoid repeated courses due to cumulative neurotoxicity risk 1, 2.

For Severe or Fulminant CDI

  • Increase vancomycin to 500 mg orally four times daily plus add intravenous metronidazole 500 mg three times daily for patients with hypotension, shock, ileus, or toxic megacolon 1, 5, 2.

  • Add rectal vancomycin 500 mg in 100 mL normal saline every 6 hours as retention enema if ileus prevents oral medication from reaching the colon 1, 5.

  • Obtain immediate surgical consultation for patients with WBC ≥25,000, lactate ≥5 mmol/L, ileus, toxic megacolon, or peritoneal signs 2, 3.

For Recurrent CDI

  • Fidaxomicin 200 mg twice daily for 10 days is preferred for first recurrence, demonstrating lower recurrence rates (15.4%) compared to vancomycin (25.3%) 5, 2.

  • Fecal microbiota transplantation (FMT) is highly effective after ≥2 recurrences, with clinical resolution rates of 87-92% compared to 40-50% with antibiotics alone 1, 5, 2, 3.

Critical Action: Stop the Offending Antibiotic

The single most important intervention is to discontinue Augmentin or any other inciting antibiotic immediately if the patient is currently taking it 1, 5, 2, 3. Continued use of the offending antibiotic decreases clinical response and increases recurrence rates 1.

  • If continued antibiotics are necessary for another infection, switch to lower-risk agents: parenteral aminoglycosides, sulfonamides, macrolides, or tetracyclines/tigecycline 2, 3.

  • Avoid high-risk antibiotics including clindamycin, third-generation cephalosporins, penicillins (including Augmentin), and fluoroquinolones, as these are strongly associated with CDI development and recurrence 2, 3.

Common Pitfalls to Avoid

  • Never use intravenous vancomycin for CDI—it is not excreted into the colon and has no efficacy against CDI; only oral or rectal vancomycin works 2, 3.

  • Do not delay treatment while waiting for laboratory confirmation in fulminant cases—start empiric therapy immediately 1.

  • Do not use Augmentin thinking it will help—it will make the infection worse by further disrupting the gut microbiome and promoting C. difficile toxin production 2, 3.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Treatment for C. difficile Diarrhea

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Treatment of C. difficile Infection

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Second-Line Treatment for C. difficile Infection After Vancomycin Failure

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.